Back to top
more

HealthEquity (HQY)

(Delayed Data from NSDQ)

$91.84 USD

91.84
642,993

+0.89 (0.98%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $91.82 -0.02 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (98 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

CVS Health (CVS) Launches Caremark Cost Saver With a New Pact

by Zacks Equity Research

CVS Health (CVS) is able to dynamically shop for the lowest price on its clients' behalf with the help of Caremark Cost Saver solution.

Zacks Equity Research

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Zacks Equity Research

Illumina's (ILMN) Latest Launch to Boost Genomics Analysis

by Zacks Equity Research

Illumina's (ILMN) DRAGEN v4.2 is expected to improve the identification of genetic disease causes, drug discovery and population genomics.

Zacks Equity Research

What's in Store for Abbott Laboratories (ABT) in Q2 Earnings?

by Zacks Equity Research

The recent FDA approvals and growing customer demand for core therapeutic lines is likely to have driven Abbott's (ABT) Q2 performance.

Zacks Equity Research

Alcon (ALC) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are bullish about Alcon (ALC) owing to solid demand, strong commercial execution and pricing improvements across the Surgical and Vision Care franchises.

Zacks Equity Research

DaVita (DVA) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about DaVita's (DVA) strength in its kidney care.

Zacks Equity Research

AngioDynamics (ANGO) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

AngioDynamics' (ANGO) fiscal fourth quarter's top line is likely to have been driven by strong demand for its products.

Zacks Equity Research

Alcon (ALC) Surgical End Market Grows, Vision Care Sales Rise

by Zacks Equity Research

In Equipment, Alcon (ALC) continues to upgrade and expand its installed base with the CENTURION and LEGION devices.

Zacks Equity Research

Here's Why Investors Should Hold Align Technology (ALGN) Now

by Zacks Equity Research

Investors are optimistic about Align Technology's (ALGN) Invisalign portfolio expansion and strategic alliances.

Zacks Equity Research

Quest Diagnostics' (DGX) New Pact to Get Home Fertility Test

by Zacks Equity Research

The Proov Confirm home collection kit can be purchased now on Quest Diagnostics' questhealth.com for $29.

Zacks Equity Research

3 Reasons to Retain PacBio (PACB) Stock in Your Portfolio

by Zacks Equity Research

PacBio's (PACB) product development activities raise optimism about the stock.

Zacks Equity Research

Reasons to Retain AMN Healthcare (AMN) Stock in Your Portfolio

by Zacks Equity Research

Investors remain optimistic about AMN Healthcare's (AMN) broad array of services.

Zacks Equity Research

HealthEquity (HQY) Down 5% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

HealthEquity (HQY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

DexCom's (DXCM) G7 CGM System Gets Nod From Health Canada

by Zacks Equity Research

DexCom's (DXCM) G7 CGM System's latest approval by Health Canada is expected to combine simplicity and power, thereby providing a better way to manage diabetes.

Zacks Equity Research

LabCorp (LH) Partners With Forge Biologics for Gene Therapies

by Zacks Equity Research

LabCorp's (LH) latest partnership will significantly assist patients gain access to cutting-edge, potentially life-saving medication.

Zacks Equity Research

3 Reasons to Retain NextGen (NXGN) Stock in Your Portfolio

by Zacks Equity Research

NextGen's (NXGN) strong product portfolio and continued demand for its solutions raise optimism about the stock.

Zacks Equity Research

Here's Why You Should Buy Exact Sciences (EXAS) Stock Now

by Zacks Equity Research

Investors are optimistic about Exact Sciences (EXAS) on strong Cologuard growth and raised guidance.

Zacks Equity Research

McKesson (MCK) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

Zacks Equity Research

Integer Holdings (ITGR) Hits 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about Integer Holdings' (ITGR) solid foothold in the broader MedTech space.

Zacks Equity Research

Quest Diagnostics (DGX) Presents New Data on Disease Testing

by Zacks Equity Research

Quest Diagnostics (DGX) is dedicated to create cutting-edge laboratory tests to help assess patient risk for dementia and other degenerative diseases.

Zacks Equity Research

Here's Why You Should Invest in Neogen (NEOG) Stock Now

by Zacks Equity Research

Investors are upbeat about Neogen (NEOG) owing to strong performance across its Animal Safety and Food Safety segments.

Zacks Equity Research

Baxter's (BAX) New Launch to Support Complex Critical Care Needs

by Zacks Equity Research

Baxter's (BAX) Progressa+ bed for the ICU is expected to enhance workflow and reduce strain on nursing resources.

Zacks Equity Research

Thermo Fisher's (TMO) New Launch to Advance Cancer Therapies

by Zacks Equity Research

Thermo Fisher's (TMO) Gibco OncoPro Tumoroid Culture Medium Kit is intended to increase researchers' access to sophisticated cancer models.

Zacks Equity Research

OPKO Health's (OPK) NGENLA Approved by FDA for GHD Treatment

by Zacks Equity Research

The latest approval for OPKO Health's (OPK) NGENLA is expected to reduce the treatment frequency from daily injections, thereby better serving the GHD patient pool.

Zacks Equity Research

Walgreens (WBA) to Advance Diabetes Care at FFL Conference

by Zacks Equity Research

Walgreens (WBA) will sponsor Children with Diabetes' FFL event to make a difference in the lives of the 122 million individuals afflicted by diabetes and pre-diabetes.